The angiogenic dormancy may be interrupted by the so called “angiogenic switch”, when any cell of the focus (cancer cell or cancer stroma cell or others) acquires the angiogenic phenotype by secreting angiogenic factors (e.g., VEGF) or downregulating angiogenic suppressors (e.g., Angiostatin [18]). Here, PLG is linked to cancer.